Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 3, 1998, Pages 408-417

  Rousso, Philippe ^a   Buclin, Thierry ^a   Nussberger, Jürg ^a   Brunner Ferber, Françoise ^b   Brunner, Hans R ^a   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SANOFI   (France)

Author keywords

ACE; Angiotensin challenge; Dose finding; Dual inhibitor; MDL 100,240; NEP

Indexed keywords

7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; [4ALPHA,7ALPHA,12BETA] 7 [2 (ACETYLTHIO) 1 OXO 3 PHENYLPROPYL]AMINO] 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXO PYRIDO [2,1 A] [2] BENZAZEPINE 4 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PRESSOR RESPONSE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BENZAZEPINES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; NEPRILYSIN; PLACEBOS; PYRIDINES; REFERENCE VALUES;

EID: 0031889227     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199803000-00012     Document Type: Article

References (30)

1. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25.
2. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1994;88:2941-52.
3. Espiner EA. Physiology of natriuretic peptides. J Intern Med 1994;235:527-41.
4. Northridge DB, Alabaster CT, Connell JMC, et al. Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 1989;2:591-3.
5. Richards M, Espiner E, Frampton C, et al. Inhibition of endopeptidase EC 24.11 in humans: renal and endocrine effects. Hypertension 1990;16:269-76.
6. Burnier M, Ganslmayer M, Perret F, et al. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Clin Pharmacol Ther 1991;50:181-91.
7. Lefrançois P, Clerc G, Duchier J, et al. Antihypertensive activity of sinorphan. Lancet 1990;336:307-8.
8. Richards AM, Crozier IG, Kosoglou T. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993;22:119-26.
9. Burnett JC Jr. The atrial peptide system in cardiac disease. Am J Hypertens 1988;1:410-20S.
10. Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-42.
11. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-83.
12. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Assad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267: 108-16.
13. Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991;17:456-65.
14. Pham I, Gonzalez W, El Amrani A-IK, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993;265:1339-47.
15. Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.
16. Stergiou GS, Hannah JA, Bevan EG, et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens 1994;12:1310-1.
17. Smits GS, McGraw DE, Trapani AJ. Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am J Physiol 1990;258:F1417-24.
18. Seymour AA, Sheldon JH, Smith PL, Assad M, Rogers WL. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs. J Pharmacol Exp Ther 1994;269:263-70.
19. Ura N, Carretero OA, Erdös EG. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987; 32: 507-13.
20. Flynn GA, French JF, Dage RC. Dual inhibitors of angiotensin converting enzyme and neutral endopeptidase: design and therapeutic rationale. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995:3099-114.
21. French JF, Flynn GA, Giroux EL, et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994;268:180-6.
22. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol 1995;26: 107-13.
23. Nussberger J, Brunner D, Keller I, Brunner HR. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II: comparison with two other methods. Am J Hypertens 1992;5:393-8.
24. Belz GG, Kirch W, Kleinbloesem CH. Angiotensin-converting enzyme inhibitors: relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet 1988;15:295-318.
25. Delacrétaz E, Nussberger J, Püchler K, et al. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1994;24:479-85.
26. Biollaz J, Burnier M, Turini GA, et al. Three new long-acting converting enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981;29:665-70.
27. Francis RJ, Brown AN, Kler L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol 1987;9:32-8.
28. Juillerat L, Nussberger J, Ménard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-72.
29. Christen Y, Waeber B, Nussberger J, Brunner HR. Noninvasive blood pressure monitoring at the finger for studying short lasting pressor responses in man. J Clin Pharmacol 1990;30:711-4.
30. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71: 1501-7.